Treatment(s) already received-Surgical removal of the tumor Posts on Medivizor
Navigation Menu

Treatment(s) already received-Surgical removal of the tumor Posts on Medivizor

Is chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?

Is chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?

Posted by on Feb 7, 2022 in Lung cancer | 0 comments

In a nutshell The study aimed to investigate the effectiveness and safety of atezolizumab (Tecentriq) versus best supportive care after chemotherapy in patients with resected early-stage non-small-cell lung cancer (NSCLC). The study showed atezolizumab is effective and has better outcomes than best supportive in these...

Read More

Evaluating the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer after surgery.

Evaluating the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer after surgery.

Posted by on Jan 20, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the predictors of early recurrence in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) after surgery. The data showed that early recurrence after surgery was associated with poor survival outcomes in patients with stage IIIA-N2 NSCLC. Smoking history, large tumor size, increased lymph node ratio, and...

Read More

Does the frequency of surveillance after surgery impact survival in patients with NSCLC?

Posted by on Sep 2, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at the frequency of follow-ups after surgical treatment in patients with non-small-cell lung cancer and whether it had an effect on survival. The study concluded that more frequent surveillance was not linked to improved survival.  Some background Surveillance during the post-treatment stage of cancer is a critical...

Read More

Comparing gene-targeting therapy to standard chemotherapy in patients with early stage NSCLC

Posted by on Apr 9, 2018 in Lung cancer | 0 comments

In a nutshell This study compared gefitinib (Iressa) to cisplatin (Platinol)-based chemotherapy for treating patients with EGFR-mutation positive, early stage non-small-cell lung cancer, after surgery. The authors concluded that while treatment with gefitinib improved disease free survival compared to chemotherapy, they were unable to calculate overall...

Read More

Looking for non-small cell lung cancer patients to study the effectiveness of a nivolumab treatment after surgery and chemotherapy

Posted by on Sep 26, 2017 in Lung cancer | 0 comments

In a nutshell This multicenter phase 3 clinical trial will test the effectiveness of nivolumab (Opdivo) after surgery and chemotherapy in stage 1b to 3a non-small cell lung cancer (NSCLC). The primary outcome will be measured by the length of time the patient survives without signs of the cancer and the overall survival rate for up to 10...

Read More

Blood protein levels could predict benefit of gefitinib in patients with advanced disease

Posted by on Dec 5, 2014 in Lung cancer | 0 comments

In a nutshell This study investigated using levels of the proteins MUC1 and VEGF to predict the benefit of gefitinib in patients with advanced NSCLC. Some background Non small-cell lung cancer (NSCLC) is a common type of lung cancer that can be difficult to treat. 65-75% of cases are presented at an advanced stage. Chemotherapy is often...

Read More

Haemoptysis predicts survival and recurrence

Posted by on Oct 1, 2013 in Lung cancer | 0 comments

In a nutshell This study investigated the prognostic role of haemoptysis in patient diagnosed with adenocarcinoma of lung and cured after surgery. Some background Haemoptysis, or bloody sputum, is a common symptom of lung cancer. Haemoptysis is thought to occur due to the invasion of the cancer into the small blood vessels of the lung. Therefore,...

Read More